For four painful tax years, one of the most punishing quirks in the entire code forced innovative companies to pay tax on money they had never actually kept. A business that spent $500,000 developing software or improving a product could deduct only a sliver of that cost in the year it was incurred — the rest had to be spread out, or amortized, over five years. Cash-strapped startups and R&D-heavy small businesses were hit with surprise tax bills on paper profits that did not exist. In 2026, that era is finally over. The One Big Beautiful Bill Act (OBBBA) restored immediate expensing of domestic research costs under Section 174 — and even lets businesses recover what they capitalized in prior years.
If your company writes code, designs products, formulates processes, or improves how you make things, this change is one of the most valuable tax developments of the year. Here is what happened, what it means, and the steps to capture it.
How We Got Here: The Section 174 Headache
Before 2022, businesses could fully deduct research and experimental (R&E) expenditures in the year they were paid — wages for engineers, software developer salaries, prototype materials, and contract research. Then a delayed provision of the 2017 Tax Cuts and Jobs Act kicked in, requiring those costs to be capitalized and amortized over five years (fifteen years for foreign research). The effect was brutal: in year one, a company could deduct only about 10% of its domestic research spending.
The result was a cash-flow shock that hit exactly the companies least able to absorb it — early-stage tech firms, manufacturers, engineering shops, and medical device developers. Many owed tax despite operating at a loss on a cash basis. It was the kind of distortion that kept our tax preparation and strategy team busy managing quarterly estimates and unpleasant surprises.
What OBBBA Changed for Section 174 in 2026
- Immediate expensing restored: domestic R&E costs are once again fully deductible in the year incurred.
- Permanent, not temporary: the deduction is written into law without a scheduled expiration.
- Retroactive relief: small businesses can amend back to 2022; others can accelerate remaining amounts.
- Foreign research unchanged: research performed outside the U.S. still amortizes over 15 years.
- Option to elect amortization: businesses may still choose to capitalize if it fits their planning.
Immediate Expensing Is Back — and Permanent
The headline is simple: for tax years beginning in 2025 and later, domestic research and experimental expenditures can be deducted in full in the year they are incurred. A software company that spends $500,000 on development in 2026 can once again claim the entire $500,000 that year instead of $50,000. That restores the immediate cash benefit that made investing in innovation financially sensible.
Because the provision is permanent, it also removes years of planning uncertainty. Businesses can build multi-year R&D budgets without guessing whether Congress will extend a temporary fix. That predictability is a gift to any owner trying to model growth — and it fits neatly into the forward-looking work our financial planning and analysis team does when mapping out research investment.
The Retroactive Catch-Up: Recovering 2022–2024 Costs
The most lucrative — and most overlooked — part of the change is retroactive. Businesses did not simply lose those amortized deductions; they were deferred. OBBBA provides two paths to recover them:
- Eligible small businesses (generally those with average annual gross receipts of $31 million or less) can amend prior returns back to 2022 and claim refunds for the tax they overpaid.
- All other businesses can accelerate the remaining unamortized balance, deducting it over the 2025 and 2026 tax years rather than waiting out the original five-year schedule.
For a company that capitalized hundreds of thousands of dollars since 2022, the catch-up can translate into a substantial refund or a large current-year deduction. Deciding whether to amend or accelerate — and modeling the cash impact of each — is exactly the kind of question worth running through our CFO and advisory team before you file.
The businesses that benefit most are the ones that document their research clearly. The deduction is only as strong as the records that prove which costs qualify.
Section 174 vs. the R&D Tax Credit: Two Different Benefits
One of the most common points of confusion is the difference between the Section 174 deduction and the Section 41 R&D tax credit. They are separate benefits, and a business can claim both.
| Feature | Section 174 Deduction | Section 41 R&D Credit |
|---|---|---|
| What it does | Deducts research costs from income | Credits tax dollar-for-dollar |
| Reduces | Taxable income | Tax owed directly |
| 2026 status | Immediate expensing restored | Available and enhanced |
| Can you claim both? | Yes — on the same qualifying research | |
Used together, they are powerful: the deduction lowers the income the research is taxed on, while the credit shaves the resulting bill. For a full breakdown of the credit side, see our guide to R&D tax credits in 2026.
Who Qualifies — and What Counts
Section 174 reaches far beyond lab coats and test tubes. Qualifying activities include software development, product design and improvement, engineering, formula and process development, and prototyping. The costs that qualify typically include:
- Wages for employees performing or directly supervising research.
- Supplies and materials consumed in the research process.
- Contract research paid to U.S.-based third parties.
- Software development costs, which are explicitly treated as R&E expenditures.
Medical and dental practices developing new procedures, custom software, or proprietary processes can qualify too — an angle our medical practice finance specialists watch for when reviewing a practice’s spending. The key in every case is clean documentation: contemporaneous records tying specific costs to specific research activities, which starts with disciplined bookkeeping throughout the year.
What to Do Now
The restoration of Section 174 is not automatic money — it rewards businesses that act deliberately. Three moves make sense before year-end:
- Quantify your capitalized balance. Add up what you have amortized since 2022 to size the potential refund or acceleration.
- Decide: amend or accelerate. If you qualify as a small business, compare the refund from amending against the simplicity of accelerating.
- Tighten your documentation. Make sure payroll, project records, and vendor invoices clearly identify qualifying research going forward.
The Bottom Line
For four years, the amortization rule punished exactly the businesses the tax code should encourage — the ones investing in building something new. OBBBA reversed that in 2026, restoring full, immediate, permanent expensing of domestic research costs and handing companies a real chance to recover taxes they overpaid since 2022. The upside is significant, but it is not self-executing: capturing it takes an accurate tally of past costs, a smart amend-or-accelerate decision, and documentation that holds up.
Wondering how much the restored Section 174 deduction could put back in your business — or whether amending prior returns is worth it? Schedule a free consultation and our tax strategy team will help you quantify the benefit and build a plan to claim every dollar you are owed.
